Observational Study of CT Dye Administration Through the Intraosseous Vascular Access Route
NCT ID: NCT01531686
Last Updated: 2016-12-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
8 participants
OBSERVATIONAL
2012-03-31
2014-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Intraosseous delivery of CT contrast dye
Delivery of CT contrast through intraosseous vascular access at the proximal humerus for CT examination.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Has received intraosseous vascular access at the proximal humerus insertion site via EZ-IO as standard of care
* Requires CT examination with contrast media delivery via proximal humerus intraosseous catheter, as standard of care
* Cognitively and physically able to give written consent to participate in the study
Exclusion Criteria
* Excessive tissue and/or absence of adequate anatomical landmarks in target bone
* Infection in target area
* IO insertion in past 24 hours, prosthetic limb or joint or other significant orthopedic procedure in target bone
* Allergy to contrast media
* Imprisoned
* Pregnant
* Requires English language translation other than Spanish
* Has received IO access with an IO catheter other than the EZ-IO system
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Vidacare Corporation
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Thomas Philbeck, PhD
Role: STUDY_DIRECTOR
Sponsor Company- Vidacare Corporation
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Maricopa Medical Center
Phoenix, Arizona, United States
Olive View UCLA Medical Center
Sylmar, California, United States
Shands Critical Care Center and Cancer Hospital
Gainesville, Florida, United States
Grand Strand Regional Medical
Myrtle Beach, South Carolina, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2011-02
Identifier Type: -
Identifier Source: org_study_id